Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCRL2 | O00421 | 17/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029606 | 0.84 | CCR2 (0.38) | CCRL2CCR2CCR5 | |
| SCHEMBL5029610 | 0.84 | CCR2 (0.38) | CCRL2CCR2CCR5 | |
| SCHEMBL5031851 | 0.74 | CCRL2 (0.54) | CCRL2 | |
| SCHEMBL5033636 | 0.73 | CCRL2 (0.55) | CCRL2 | |
| SCHEMBL5031901 | 0.73 | CCRL2 (0.71) | CCRL2 | |
| SCHEMBL5027107 | 0.72 | CCRL2 (0.51) | CCRL2CCR2 | |
| SCHEMBL5027128 | 0.71 | CALCA (0.38) | CCR2 | |
| SCHEMBL5027259 | 0.71 | CCRL2 (0.53) | CCRL2 | |
| SCHEMBL5031899 | 0.71 | CCRL2 (0.50) | CCRL2CCR2 | |
| SCHEMBL18860349 | 0.70 | CCR2 (0.78) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCRL2 15/4885CCR2 3/4885CCR5 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.